406 related articles for article (PubMed ID: 19780597)
1. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
Udommaneethanakit T; Rungrotmongkol T; Bren U; Frecer V; Stanislav M
J Chem Inf Model; 2009 Oct; 49(10):2323-32. PubMed ID: 19780597
[TBL] [Abstract][Full Text] [Related]
2. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1.
Malaisree M; Rungrotmongkol T; Decha P; Intharathep P; Aruksakunwong O; Hannongbua S
Proteins; 2008 Jun; 71(4):1908-18. PubMed ID: 18175324
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
Feng E; Ye D; Li J; Zhang D; Wang J; Zhao F; Hilgenfeld R; Zheng M; Jiang H; Liu H
ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317
[TBL] [Abstract][Full Text] [Related]
4. Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
Pan P; Li L; Li Y; Li D; Hou T
Antiviral Res; 2013 Nov; 100(2):356-64. PubMed ID: 24055835
[TBL] [Abstract][Full Text] [Related]
5. Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.
Tran-To Su C; Ouyang X; Zheng J; Kwoh CK
BMC Bioinformatics; 2013; 14 Suppl 16(Suppl 16):S7. PubMed ID: 24564719
[TBL] [Abstract][Full Text] [Related]
6. Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)".
Rungrotmongkol T; Malaisree M; Udommaneethanakit T; Hannongbua S
Biophys Chem; 2009 Apr; 141(1):131-2; author reply 133. PubMed ID: 19231807
[No Abstract] [Full Text] [Related]
7. Drugs against avian influenza a virus: design of novel sulfonate inhibitors of neuraminidase N1.
Udommaneethanakit T; Rungrotmongkol T; Frecer V; Seneci P; Miertus S; Bren U
Curr Pharm Des; 2014; 20(21):3478-87. PubMed ID: 24001233
[TBL] [Abstract][Full Text] [Related]
8. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.
Singh A; Soliman ME
Drug Des Devel Ther; 2015; 9():4137-54. PubMed ID: 26257512
[TBL] [Abstract][Full Text] [Related]
9. Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus.
Park JW; Jo WH
Eur J Med Chem; 2010 Feb; 45(2):536-41. PubMed ID: 19914748
[TBL] [Abstract][Full Text] [Related]
10. Neuraminidase inhibitor resistance in influenza viruses.
Reece PA
J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
Hurt AC; Selleck P; Komadina N; Shaw R; Brown L; Barr IG
Antiviral Res; 2007 Mar; 73(3):228-31. PubMed ID: 17112602
[TBL] [Abstract][Full Text] [Related]
12. Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach.
Mai BK; Li MS
Biochem Biophys Res Commun; 2011 Jul; 410(3):688-91. PubMed ID: 21693105
[TBL] [Abstract][Full Text] [Related]
13. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
Baek YH; Song MS; Lee EY; Kim YI; Kim EH; Park SJ; Park KJ; Kwon HI; Pascua PN; Lim GJ; Kim S; Yoon SW; Kim MH; Webby RJ; Choi YK
J Virol; 2015 Jan; 89(1):287-99. PubMed ID: 25320319
[TBL] [Abstract][Full Text] [Related]
14. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir.
Park JW; Jo WH
J Chem Inf Model; 2009 Dec; 49(12):2735-41. PubMed ID: 19957991
[TBL] [Abstract][Full Text] [Related]
15. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.
Liu H; Yao X; Wang C; Han J
Mol Pharm; 2010 Jun; 7(3):894-904. PubMed ID: 20420444
[TBL] [Abstract][Full Text] [Related]
16. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
[TBL] [Abstract][Full Text] [Related]
17. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
Du QS; Wang SQ; Chou KC
Biochem Biophys Res Commun; 2007 Oct; 362(2):525-31. PubMed ID: 17707775
[TBL] [Abstract][Full Text] [Related]
18. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
[TBL] [Abstract][Full Text] [Related]
19. Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation.
Malaisree M; Rungrotmongkol T; Nunthaboot N; Aruksakunwong O; Intharathep P; Decha P; Sompornpisut P; Hannongbua S
Amino Acids; 2009 Oct; 37(4):725-32. PubMed ID: 19002747
[TBL] [Abstract][Full Text] [Related]
20. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.
Collins PJ; Haire LF; Lin YP; Liu J; Russell RJ; Walker PA; Skehel JJ; Martin SR; Hay AJ; Gamblin SJ
Nature; 2008 Jun; 453(7199):1258-61. PubMed ID: 18480754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
